Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Mobile Mini, Inc. (NASDAQ: MINI), Avanir Pharmaceuticals Inc (NASDAQ: AVNR), Mcgrath Rentcorp (NASDAQ: MGRC), Human Genome Sciences (NASDAQ: HGSI), Oiltanking Partners (NASDAQ: OILT) and Medgenics (NASDAQ: MDGN) getting new analyst coverage.
Keybanc initiated coverage on Mobile Mini, Inc. (MINI). They placed a “Hold” rating on the company.
Summer Street Research initiated coverage on Onyx Pharmaceuticals, Inc. (ONXX). They placed a “Buy” rating and a price target of $49.00 on the company.
JMP Securities initiated coverage on Avanir Pharmaceuticals Inc (AVNR). They placed an “outperform” rating and a price target of $7.00 on the company.
Keybanc initiated coverage on Mcgrath Rentcorp (MGRC). They placed a “Buy” rating and a price target of $28.00 on the company.
Brean Murray initiated coverage on Human Genome Sciences (HGSI). They placed a “Buy” rating and a price target of $22.00 on the company.
Raymond James (NYSE:RJF) initiated coverage on Oiltanking Partners (OILT). They placed an “Outperform” rating on the company.
Maxim Group initiated coverage on Medgenics (MDGN). They placed a “Buy” rating and a price target of $8.00 on the company.
Showing posts with label Avanir Pharmaceuticals. Show all posts
Showing posts with label Avanir Pharmaceuticals. Show all posts
Wednesday, August 24, 2011
Wednesday, May 11, 2011
Ratings on (AGO) (AONE) (AVNR) (AXAS) (BAP) Reiterated
Ratings on Assured Guaranty Ltd (NYSE: AGO), A123 Systems, Inc. (NASDAQ: AONE), Avanir Pharmaceuticals Inc (NASDAQ: AVNR), Abraxas Petroleum Corp. (NASDAQ: AXAS) and Credicorp Ltd. (NYSE: BAP) reiterated by analysts.
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Assured Guaranty Ltd (AGO). They have a price target of $25.00 on the company.
Wunderlich reiterated a “sell” rating on A123 Systems, Inc. (AONE). They now have a price target of $3.50 on the company.
Wedbush reiterated an “outperform” rating on Avanir Pharmaceuticals Inc (AVNR).
Wunderlich reiterated a “buy” rating on Abraxas Petroleum Corp. (AXAS).
Goldman Sachs (NYSE:GS) reiterated a “neutral” rating on Credicorp Ltd. (BAP).
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Assured Guaranty Ltd (AGO). They have a price target of $25.00 on the company.
Wunderlich reiterated a “sell” rating on A123 Systems, Inc. (AONE). They now have a price target of $3.50 on the company.
Wedbush reiterated an “outperform” rating on Avanir Pharmaceuticals Inc (AVNR).
Wunderlich reiterated a “buy” rating on Abraxas Petroleum Corp. (AXAS).
Goldman Sachs (NYSE:GS) reiterated a “neutral” rating on Credicorp Ltd. (BAP).
Tuesday, December 21, 2010
Avanir Pharmaceuticals' (NASDAQ:AVNR) Nuedexta Launch Should be Strong
Citing an expected strong launch of Nuedexta by Avanir Pharmaceuticals' (NASDAQ:AVNR) in February 2011, Canaccord things starting to take off for the company in the 2nd half of the year.
Canaccord said, "Reiterate rating and PT on good Nuedexta February 2011 launch and strong H2/11 commercial uptake. We think AVNR will drive strong PBA awareness and continue strong clinician/patient outreach. We predict strong Nuedexta launch in Feb. 2011 and good uptake starting H2/11. Our $10 target is based on a sum-of-the-parts analysis...Nuedexta sales force, commercial infrastructure in place, reimbursement and supply strategy being finalized...Doctors are conceptually aware of PBA, but may not recognize real world systems...Phase 2 trials in new indications in 2011; EMA meeting on track for mid-2011."
Canaccord Genuity maintains a "Buy" on Avanir Pharmaceuticals, which closed Monday at $4.05, up $0.06, or 1.50 percent. Canaccord has a price target on them of $10.
Canaccord said, "Reiterate rating and PT on good Nuedexta February 2011 launch and strong H2/11 commercial uptake. We think AVNR will drive strong PBA awareness and continue strong clinician/patient outreach. We predict strong Nuedexta launch in Feb. 2011 and good uptake starting H2/11. Our $10 target is based on a sum-of-the-parts analysis...Nuedexta sales force, commercial infrastructure in place, reimbursement and supply strategy being finalized...Doctors are conceptually aware of PBA, but may not recognize real world systems...Phase 2 trials in new indications in 2011; EMA meeting on track for mid-2011."
Canaccord Genuity maintains a "Buy" on Avanir Pharmaceuticals, which closed Monday at $4.05, up $0.06, or 1.50 percent. Canaccord has a price target on them of $10.
Subscribe to:
Posts (Atom)